Clinical Trials Logo

Filter by:
NCT ID: NCT05507996 Terminated - Menkes Syndrome Clinical Trials

Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome

Start date: August 18, 2022
Phase: Early Phase 1
Study type: Interventional

It is a single-center, open, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of recombinant adeno-associated virus administration for patients with Menkes syndrome.

NCT ID: NCT05489679 Terminated - Breast Cancer Clinical Trials

A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: 1. To evaluate the safety and tolerability of AC682 2. To evaluate the pharmacokinetic of AC682 3. To evaluate the preliminary anti-tumor activity of AC682

NCT ID: NCT05470933 Terminated - Clinical trials for Advanced Solid Tumors

A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors

Start date: August 23, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I study to Investigate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJ01075 tablets in patients with advanced malignant solid tumors, including phase Ia (dose escalation phase) and Phase Ib (dose expansion phase,cohort expansion phase).The study includes screening, treatment and follow-up periods. In phase Ia, accelerated titration (the first two dose groups) and "3 + 3" combination (the subsequent dose group) were used for dose escalation. In phase Ib, specific dose groups will be selected for dose expansion according to PK(Pharmacokinetics) and safety data of different dose groups in dose escalation phase.It is planned that SMC(Safety Monitoring Committee) will select one or more dose groups based on previous data for cohort expansion studies to further determine RP2D, safety tolerability and initial efficacy.

NCT ID: NCT05461794 Terminated - Clinical trials for Esophageal Squamous Cell Carcinoma

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Start date: October 3, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of sitravatinib in combination with tislelizumab for the treatment of participants with esophageal squamous cell carcinoma

NCT ID: NCT05405439 Terminated - Clinical trials for Metastatic Castration-resistant Prostate Cancer

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Start date: August 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II clinical study to explore the safety and efficacy of TQB3823 tablets combined with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.

NCT ID: NCT05388279 Terminated - Clinical trials for Advanced or Metastatic Solid Tumors

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Start date: April 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS012 monotherapy and combination with chemotherapy in patients with Advanced or Metastatic Solid Tumors.

NCT ID: NCT05381363 Terminated - COVID-19 Clinical Trials

Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children

Start date: January 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

In the COVID-19 pandemic era, a convenient and effective treatment for pediatric patients is unavailable. A multi-center Chinese clinical trials with the aim to using Interferon-α2b spray inhalation to develop new treatment strategies for the treatment of pediatric patients with mild or moderate type of COVID-19. The purpose of this study is to determine the safety and efficacy for Interferon α2b spray inhalation as first line treatment.

NCT ID: NCT05379452 Terminated - SARS-CoV2 Infection Clinical Trials

Outcomes of Neonates Born to Mothers With SARS-CoV-2 Infection in Shanghai

Start date: March 1, 2022
Phase:
Study type: Observational

Since March 2022, there are an outbreak of SARS-CoV-2 infection (Omicron) in Shanghai. This cohort study aims to analysis the clinical outcomes of neonates born to mothers with SARS-CoV-2 infection.

NCT ID: NCT05361356 Terminated - Adult ALL Clinical Trials

Spectral CT Clinical Trial

Start date: March 10, 2022
Phase: N/A
Study type: Interventional

The objective of this clinical trial was to evaluate the efficacy, ease of operation, stability, and safety of Spectral CT as expected.

NCT ID: NCT05354362 Terminated - Clinical trials for Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

MATCH
Start date: March 2, 2022
Phase: Phase 1
Study type: Interventional

This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)